Rex Bionics plc and Deltason establish Partnership to commercialise the REX Robot in Hong Kong

2015-05-04

Rex Bionics plc and Deltason Medical Ltd are pleased to announce that they have signed a distribution agreement in which Deltason will exclusively represent the REX robot in Hong Kong - in neuro-rehabilitation clinics and in the personal use market. Deltason will launch REX at the Hong Kong International Medical Devices and Supplies Fair (May 18-20).

Tommy Chan, Director Deltason Medical Ltd said “We are very pleased to have been chosen as Rex’s representative in Hong Kong and believe that there is a good opportunity here for this exciting technology”.

Crispin Simon, Chief Executive, Rex Bionics plc said “We are delighted with our partnership with Deltason. Hong Kong is an important market and Deltason has an excellent reputation for service and innovation and long-standing relationships in the rehabilitation community.” “We are in discussion with distribution partners of a similar quality in other countries and plan to establish coverage in most of the important markets over the next 24 months”.

About Deltason

Deltason Medical Limited is a 20-year old, well established distributor of rehabilitation equipment in Hong Kong, China and has a strong presence in neurology and stroke rehabilitation. Deltason is headquartered in Hong Kong, China with approximately 80 employees, a sub branch office at Beijing, 30 direct sales representatives and over 30 local sub-dealers throughout mainland China. Deltason is the distributor for more than 30 rehabilitation product lines developed by some of the global industry leaders, and focuses on marketing innovative products to healthcare professionals who demand superior quality. Over the years, Deltason has established a reputation of rigorous quality, unique products, profound knowledge and excellent customer service.

About Rex Bionics

Rex Bionics (AIM: RXB) is the UK AIM-listed pioneer of the REX Robot that enhances the mobility of wheel-chair users. Founded in Auckland, New Zealand by two robotics engineers with first-hand experience of wheelchair users and their needs, Rex Bionics is working with physiotherapists to develop the practice of Robot-Assisted Physiotherapy (RAP). In a session of RAP, REX lifts patients from a sitting position into a robot-supported standing position, allowing them to take part in a set of supported walking and stretching exercises, designed by specialist physiotherapists.

Wheelchair users are at risk of developing numerous medical complications from extended periods of sitting. By enabling them to spend more time standing, walking and exercising, REX may offer significant health benefits, including improved sleep, cardiovascular performance, maintenance of joint range, and a reduction in common abdominal problems and prescription drug use. A programme of clinical trials is now under way to evaluate these potential benefits.

REX is used by people with complete spinal cord injury, as well as people who have suffered a stroke or other traumatic brain injury; and people with multiple sclerosis and muscular dystrophy. REX P, for use in the home, enables users to walk and stand with their hands free - providing more work and recreation options.

In May 2014, Rex Bionics joined AIM with a fundraising of £10 million (gross) to scale up production, distribution and marketing internationally, in order to support growing demand for both REX products as well as developing the next generation of REX devices, REX 3.

REX is not approved for At-Home use in the United States of America.